Literature DB >> 26299413

Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis.

Javier Ampuero1, Macarena Simón2, Carmina Montoliú3, Rodrigo Jover4, Miguel Ángel Serra5, Juan Córdoba2, Manuel Romero-Gómez6.   

Abstract

BACKGROUND & AIMS: Minimal hepatic encephalopathy (MHE) is associated with falls, traffic accidents, and overt HE. However, the association with survival is controversial. We assessed the effects of MHE on the long-term survival of patients with cirrhosis.
METHODS: We performed a prospective study of 117 consecutive patients with cirrhosis seen at a tertiary hospital in Seville, Spain (estimation cohort), followed by a validation study of 114 consecutive patients with cirrhosis seen at 4 hospitals in Spain from January 2004 through December 2007. Patients were examined every 6 months at outpatient clinics through December 2013 (follow-up periods of 5 ± 2.8 y and 4.4 ± 3.9 y for each group, respectively). Cirrhosis was identified by liver biopsy, ultrasound, endoscopic analysis, and biochemical parameters. Liver dysfunction was determined based on model for end-stage liver disease (MELD) and Child-Pugh scores. All patients were administered the critical flicker frequency (CFF) test and psychometric hepatic encephalopathy scores were used to detect MHE. Survival curves were compared using the log-rank test and multivariable analysis was performed using Cox proportional hazards models.
RESULTS: The distributions of Child-Pugh scores were as follows: 66% class A, 31% class B, and 3% class C in the estimation cohort, and 50% class A, 32% class B, and 18% class C in the validation cohort. In the estimation cohort, 24 of 35 patients (68.6%) with a CFF score less than 39 Hz survived for 5 years, whereas 50 of 61 patients (82%) with a CFF score of 39 Hz or higher survived during the follow-up period (log-rank score, 5.07; P = .024). Psychometric hepatic encephalopathy scores did not correlate with survival. In multivariable analysis, older age (hazard ratio [HR], 1.07; 95% confidence interval [CI], 1.02-1.12; P = .009), CFF score less than 39 Hz (HR, 4.36; 95% CI, 1.67-11.37; P = .003), and MELD score (HR, 1.40; 95% CI, 1.21-1.63; P = .0001) were associated independently with survival during the follow-up period. In the validation cohort, CFF score less than 39 Hz and MELD score also were associated with patient survival during the follow-up period. MHE had no effect on the survival of patients with MELD scores less than 10 (among patients with CFF scores ≥39 Hz, 94.5% survived for 5 years vs 91.9% of patients with CFF scores <39 Hz; log-rank score, 0.64; P = .423). Fewer patients with MELD scores of 10-15 and MHE survived for 5 years (44.4%; 12 of 27) than those with MELD scores greater than 15 without MHE (61.5%; 8 of 13) (P < .05). Only 2 of 12 patients (16.7%) with MELD scores of 15 or higher and MHE survived for 5 years (log-rank score, 90.56; P = .0001).
CONCLUSIONS: MHE is associated with a reduced 5-year survival rate of patients with cirrhosis. Evaluation of MHE could help predict survival times and outcomes of patients with specific MELD scores. The CFF could help physicians determine prognoses of patients with cirrhosis.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Liver Fibrosis; Mortality; PHES; Prognostic Factor

Mesh:

Year:  2015        PMID: 26299413     DOI: 10.1053/j.gastro.2015.07.067

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  33 in total

Review 1.  Advances in psychometric tests for screening minimal hepatic encephalopathy: From paper-and-pencil to computer-aided assessment.

Authors:  Ming Luo; Ping Ma; Lei Li; Wu-Kui Cao
Journal:  Turk J Gastroenterol       Date:  2019-05       Impact factor: 1.852

Review 2.  Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy.

Authors:  Lise L Gluud; Rebecca Jeyaraj; Marsha Y Morgan
Journal:  J Clin Exp Hepatol       Date:  2019-02-15

3.  Hippocampal atrophy and functional connectivity disruption in cirrhotic patients with minimal hepatic encephalopathy.

Authors:  Weiwen Lin; Xuhui Chen; Yong-Qing Gao; Zhe-Ting Yang; Weizhu Yang; Hua-Jun Chen
Journal:  Metab Brain Dis       Date:  2019-07-30       Impact factor: 3.584

4.  Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis.

Authors:  Elliot B Tapper; Devin Aberasturi; Zhe Zhao; Chia-Yang Hsu; Neehar D Parikh
Journal:  Aliment Pharmacol Ther       Date:  2020-05-03       Impact factor: 8.171

5.  The Predicament of the PREDICT Study!!

Authors:  Chandan K Kedarisetty; Vanarasi Y Bhargav; Mu Karthikeyan; Bernard Wc Sathiyasekaran; Jayanthi Venkataraman
Journal:  J Clin Exp Hepatol       Date:  2019-11-22

6.  Specific Gut and Salivary Microbiota Patterns Are Linked With Different Cognitive Testing Strategies in Minimal Hepatic Encephalopathy.

Authors:  Jasmohan S Bajaj; Andrew Fagan; Melanie B White; James B Wade; Phillip B Hylemon; Douglas M Heuman; Michael Fuchs; Binu V John; Chathur Acharya; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Am J Gastroenterol       Date:  2019-07       Impact factor: 10.864

7.  Screening for minimal hepatic encephalopathy in patients with cirrhosis by cirrhosis-related symptoms and a history of overt hepatic encephalopathy.

Authors:  Emi Yoshimura; Tatsuki Ichikawa; Hisamitsu Miyaaki; Naota Taura; Satoshi Miuma; Hidataka Shibata; Takuya Honda; Fuminao Takeshima; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2016-06-13

8.  Diagnosis of minimal hepatic encephalopathy in a tertiary care center from eastern Romania: validation of the psychometric hepatic encephalopathy score (PHES).

Authors:  Mircea Alexandru Badea; Vasile Liviu Drug; Mihaela Dranga; Otilia Gavrilescu; Gabriela Stefanescu; Iolanda Popa; Catalina Mihai; Cristina Cijevschi-Prelipcean
Journal:  Metab Brain Dis       Date:  2016-07-27       Impact factor: 3.584

9.  Brain Training with Video Games in Covert Hepatic Encephalopathy.

Authors:  Jasmohan S Bajaj; Vishwadeep Ahluwalia; Leroy R Thacker; Andrew Fagan; Edith A Gavis; Michael Lennon; Douglas M Heuman; Michael Fuchs; James B Wade
Journal:  Am J Gastroenterol       Date:  2016-12-13       Impact factor: 10.864

10.  Patient Acceptance of Lactulose Varies Between Indian and American Cohorts: Implications for Comparing and Designing Global Hepatic Encephalopathy Trials.

Authors:  Sahaj Rathi; Andrew Fagan; James B Wade; Madhu Chopra; Melanie B White; Dinesh Ganapathy; Chathur Acharya; Radha K Dhiman; Jasmohan S Bajaj
Journal:  J Clin Exp Hepatol       Date:  2017-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.